RxDoctor Payments Data

Makeba Thomas, NP

Nurse Practitioner · Fort Worth, TXNPI 1770981730

Payments from drug & device makers

$2,042in general payments, 2019–2025

Across 33 payments — averaging $61.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$1K
  • AstraZeneca$725
  • Jazz Pharmaceuticals Inc.$139
  • Regeneron Healthcare Solutions, Inc.$30
  • GSK$25
  • Verona Pharma, Inc.$24

What the payments were for

  • Travel & lodging$94646%
  • Food & beverage$99649%
  • Education$1005%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,042 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$111,886
Medicare patients
719
Services billed
1,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter172$138,347
Fasenra PenBenralizumab11$65,645
Breztri AerosphereBudesonide/Glycopyr/Formoterol91$64,925
XolairOmalizumab18$32,508
Stiolto RespimatTiotropium Br/Olodaterol Hcl32$20,363
Breo ElliptaFluticasone/Vilanterol38$16,098
SymbicortBudesonide/Formoterol Fumarate54$14,696
Spiriva RespimatTiotropium Bromide17$13,087
Combivent RespimatIpratropium/Albuterol Sulfate14$8,985
Fluticasone-SalmeterolFluticasone Propion/Salmeterol49$6,111
Albuterol Sulfate HfaAlbuterol Sulfate139$3,261
Azelastine Hcl23$1,091
Ventolin HfaAlbuterol Sulfate18$1,014
Gabapentin62$903
Ropinirole Hcl31$780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$25$154,445210 claims
AstraZenecaBreztri Aerosphere, Symbicort$725$79,621145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →